Published Saudi Arabia Study Confirms TruScreen's Results

NZX/ASX Announcement

1 May 2025

Published Saudi Arabia study confirms TruScreen’s high sensitivity and specificity compared to pap smear

TruScreen Group Limited (NZX/ASX:TRU) is pleased to share that the preliminary publication in July 2024 of a Saudi Arabia study investigating TruScreen’s performance versus pap smears in cervical cancer detection, has now been peer reviewed and published by globally renowned BMC Women’s Health.

The study, entitled “Beyond Tradition: Investigating TruScreen’s Performance Versus Pap Smear in Cervical Cancer Detection” 1 tested 507 women and was first published on Research Square1 Link on 25 July 2024. Results showed that TruScreen demonstrated:

• High Sensitivity: Truscreen 83.3%, compared to Pap Smear 66.7%
• High Specificity: Truscreen 95%, compared to Pap Smear 98.2%

The authors concluded that TruScreen “represents a reliable, practical screening tool for cervical neoplasms” and that their results “provide an evidence-based approach for policymakers when selecting the optimal cervical cancer screening strategy in countries without an established national screening program.”

BMC’s peer review2 outlines TruScreen’s “potential as a screening tool for cervical neoplasms” and also highlights that “the tool did not require cervical samples, laboratory equipment, or highly trained personnel.” Further research is encouraged.

BMC Women's Health is an open access, peer-reviewed journal that considers articles on all aspects of the health and wellbeing of adolescent girls and women, with a particular focus on the physical (including gynecological diseases), mental, and emotional health of women in developed and developing nations.

This announcement has been approved by the Board.

ENDS


For more information, visit www.truscreen.com or contact:

Martin Dillion
Chief Executive Officer
[email protected]

Guy Robertson
Chief Financial Officer
[email protected]

---

Announcement PDF